This article presents views of a discipline termed safety pharmacology or general pharmacology. This is an area that provides information through empirical studies on new pharmacologic agents at doses above those thought to be efficacious and the no-toxicologic-effect level (NOEL) above which unwanted effects might occur. The usefulness of batteries of tests is discussed, and comments are made about the value of these in the drug developmental process.
Dean, J. H., and Olson, H. M.1993. The integration of investigative toxicology in the drug discovery process. Biol. Cell77:3–8.
2.
Fossa, A. A., and Buchholz, R. A.1994. Interrelationship of general pharmacology studies with drug discovery and development, clinical medicine, and regulatory affairs. Drug Dev. Res.32:217–222.
3.
Kinter, L. B., Gossett, K. A., and Kerns, W. D.1994. Status of safety pharmacology in the pharmaceutical industry, 1993. Drug Dev. Res.32:208–216.
4.
Lumley, C. E.1994. General pharmacology, the international regulatory environment, and harmonization of guidelines. Drug Dev. Res.32:223–232.
5.
Proakis, A. G.1994. Regulatory considerations on the role of general pharmacology studies in the development of therapeutic agents. Drug Dev. Res.32:233–236.
6.
Williams, P. D.1990. The role of pharmacological profiling in safety assessment. Regul. Toxicol. Pharmacol.12:238–252.
7.
Zbinden, G.1984. Neglect of function and obsession with structure in toxicity testing. Proceedings, 9th International Congress of Pharmacology, Vol. I, 43–49. New York: Macmillan.
